Table 4. Top 10 metabolites predicted as suitable drug candidates against VIBPA Type II secretion system protein L and VIBPA Putative fimbrial protein Z.

Novel Targets	HMDB ID	Binding Energy	Name	Drug Bank ID	Drug Name	Drug Group
VIBPA Type II secretion system protein L (Q87TC9)	HMDB0004971	-10.6	Glucosylceramide (d18:1/16:0)	DB09039	Eliglustat	Approved
	HMDB0004972	-10.5	Glucosylceramide (d18:1/18:0)	DB09039	Eliglustat	Approved
	HMDB0004970	-10.3	Glucosylceramide (d18:1/9Z-18:1)	DB09039	Eliglustat	Approved
	HMDB0004976	-10.3	Glucosylceramide (d18:1/26:1(17Z))	DB09039	Eliglustat	Approved
	HMDB0008646	-10.3	PC(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))	DB00641	Simvastatin	Approved
	HMDB0011300	-10.1	PC(P-18:1(11Z)/P-18:1(11Z)	DB00334	Olanzipine	Approved, Investigational
	HMDB0008443	-9.7	PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))	DB00641	Simvastatin	Approved
	HMDB0008138	-9.6	PC(18:2(9Z,12Z)/18:2(9Z,12Z))	DB00641	Simvastatin	Approved
	HMDB0004973	-9.5	Glucosylceramide (d18:1/20:0)	DB09039	Eliglustat	Approved
	HMDB0010348	-9.5	Dehydroepiandrosterone 3-glucuronide	DB01708	Prasterone	Approved, Investigationa, Nutraceutical
VIBPA Putative fimbrial protein Z (Q87I65)	HMDB0004972	-9.6	Glucosylceramide (d18:1/18:0)	DB09039	Eliglustat	Approved
	HMDB0002308	-9.5	Hydroxocobalamin	DB00200	Hydroxocobalamin	Approved
	HMDB0004970	-9.3	Glucosylceramide (d18:1/9Z-18:1)	DB09039	Eliglustat	Approved
	HMDB0004971	-9.3	Glucosylceramide (d18:1/16:0)	DB09039	Eliglustat	Approved
	HMDB0002174	-9.1	Cobalamin	DB14098	Cobalamin	Experimental
	HMDB0008646	-8.9	PC(22:4(7Z,10Z,13Z,16Z)/22:4(7Z,10Z,13Z,16Z))	DB00641	Simvastatin	Approved
	HMDB0060546	-8.9	Norbuprenorphine	DB01026	Ketoconazole	Approved, Investigational
	HMDB0041936	-8.7	Morphine-3-glucuronide	DB00295	Morphine	Approved, Investigational
	HMDB0004974	-8.6	Glucosylceramide (d18:1/22:0)	DB09039	Eliglustat	Approved
	HMDB0008443	-8.5	PC(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))	DB00641	Simvastatin	Approved